CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

PURPOSE: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. METHODS: Participants with chronic pain (94% on...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Genet Med
Main Authors: Smith, D. Max, Weitzel, Kristin W., Elsey, Amanda R., Langaee, Taimour, Gong, Yan, Wake, Dyson T., Duong, Benjamin Q., Hagen, Melanie, Harle, Christopher A., Mercado, Elvira, Nagoshi, Ying, Newsom, Kimberly, Wright, Ashleigh, Rosenberg, Eric I., Starostik, Petr, Clare-Salzler, Michael J., Schmidt, Siegfried O., Fillingim, Roger B., Johnson, Julie A., Cavallari, Larisa H.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650382/
https://ncbi.nlm.nih.gov/pubmed/30670877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41436-018-0431-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares